Paris (ots/PRNewswire) - The Partnering for Cure faculty of experts today announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV). As ...
Paris (ots/PRNewswire) - - The SHE network continues to expand across Europe to empower and educate women living with HIV and their health care providers - More than 60 SHE units, multidisciplinary teams based in HIV clinics and dedicated to women with HIV, have been implemented in 18 countries 'SHE' (Strong, HIV ...
Paris (ots/PRNewswire) - Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology community In advance of this year's International Liver CongressTM 2014 in London, ...
Paris (ots/PRNewswire) - First-ever, Europe-wide scientific initiative designed to accelerate virology clinical research & transform clinical outcomes for patients Three European virology researchers were awarded research grants this week based on their proposed research projects to investigate novel ways to cure ...
Paris, France (ots/PRNewswire) - Yervoy, an innovative immuno-oncology therapy that has demonstrated durable long-term survival in some patients,[1],[2] is now approved for use in previously-untreated patients Bristol-Myers Squibb today announced that the European Commission (EC) has approved YERVOY(R) (ipilimumab) ...
Princeton, New Jersey (ots/PRNewswire) - - In this pooled analysis of 12 studies, a plateau in the survival curve begins at approximately three years, with some patients followed for up to ten years - Three-year estimated survival rate of 22% observed in patients treated with ipilimumab - Findings are based on ...
Paris (ots/PRNewswire) - AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable ...
Princeton, New Jersey (ots/PRNewswire) - Intended only for European media based outside of the UK - 53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage ...
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...
Paris (ots/PRNewswire) - Proven biologic is first therapy available in both subcutaneous and intravenous formulations for adults with moderate to severe active rheumatoid arthritis Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA(R) (abatacept), in combination with ...
Princeton, New Jersey (ots/PRNewswire) - - Long-Term Follow Up From Phase 3 Study (024) Demonstrated That 19.0 Percent of Treatment-Naïve Patients Who Received YERVOY at Investigational Dose of 10 mg/kg Plus Dacarbazine (DTIC) Were Alive at Four Years vs. 9.6 Percent of Patients Treated with DTIC Alone - Few New ...
Paris (ots/PRNewswire) - ? - ORENCIA demonstrated comparable efficacy to HUMIRA based on a non-inferiority endpoint for ACR20 response at 1 year - Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months - AMPLE is the first head-to-head study in ...
Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] today announced that the company will present 18 abstracts on abatacept ...
Paris, November 25 (ots/PRNewswire) - - REYATAZ(R) is the only boosted PI to include dosing and medical guidance in pregnancy and postpartum in the label - Bristol-Myers Squibb Company today announced that the European Commission approved a labelling update for REYATAZ(R) (atazanavir sulfate) based on new data ...
Paris (ots/PRNewswire) - - First and Only Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival - First EU-Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma in More Than Two Decades Bristol-Myers Squibb today announced ...
Paris (ots/PRNewswire) - - European Commission approves NULOJIX(R) (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor antagonist at induction, for prophylaxis of graft rejection in adult patients receiving a kidney transplant - First new mode of action for prevention of graft rejection in kidney transplantation in a ...
Paris (ots/PRNewswire) - Five-year follow-up results were presented today from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia(CP-CML) adult patients resistant or intolerant to imatinib mesylate. At ...
Princeton, New Jersey (ots/PRNewswire) - - Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone - Forty-Seven Percent of Patients Treated with YERVOY Plus Dacarbazine Alive at One Year, 28 Percent Alive at Two Years ...
Paris (ots/PRNewswire) - YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP's positive opinion in its decision on ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukaemia in Chronic Phase ...
Princeton, New Jersey and Tokyo (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and Otsuka Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the Phase 3 DASISION study of SPRYCEL(R) (dasatinib) 100 mg once daily vs. imatinib (400 mg daily) in the first-line treatment ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(r) (dasatinib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive Chronic Myelogenous Leukaemia in Chronic ...
Cologne, Germany, November 12 (ots/PRNewswire) - - With Women Comprising Over Half of the Global HIV/AIDS Population,(1) Leading Experts to Convene to Explore the Impact of Gender on Treatment and Care With 33 million individuals infected, HIV/AIDS has long been classified as a global epidemic.(1) But with 17 million women between the ages of 15 and 49 years who are living with HIV/AIDS and its significant ...
Princeton, New Jersey (ots/PRNewswire) - New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3. Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on ...
London (ots/PRNewswire) - - Between 15 to 38 percent of HIV-infected persons in Europe do not present for screening and treatment until late in infection.(1) Late presentation has been show to result in increased morbidity(1) and decreasing quality of life.(2,3) Almost three decades after the discovery of HIV/AIDS, and despite big medical advances, there ...